(RTTNews) - Femasys Inc. (FEMY), a biomedical company, on Tuesday announced the receipt of regulatory approvals from the Israeli Medical Device Division of the Ministry of Health or AMAR for three of ...
ATLANTA, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to ...
ATLANTA, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of ...
Femasys ( (FEMY)) has provided an announcement. On December 18, 2025, Femasys Inc. reported that it had received 510(k) clearance from the U.S. Food and Drug Administration for its FemVue Controlled ...
Femasys Inc. has announced the approval from the UK's Medicines & Healthcare products Regulatory Agency (MHRA) for its FemaSeed® Intratubal Insemination product, along with two diagnostic devices, ...
Revenue surged 84.8% to $0.41 million (GAAP) in Q2 2025, far outpacing consensus estimates (GAAP) but still early-stage in scale. FemBloc gained its first-ever European approval; FemaSeed and FemVue ...
ATLANTA, March 22, 2012 /PRNewswire/ --Femasys Inc., an emerging medical device developer of women's healthcare solutions, today announced an agreement with Bayer Yakuhin, Ltd., Osaka, Japan, for ...
Biomedical company Femasys has secured CE mark certification and Health Canada approval for FemVue MINI, a compact solution for assessing fallopian tubes. Designed for in-office use, the FemVue MINI ...
ATLANTA, July 01, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide, with a broad portfolio of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results